var data={"title":"Risperidone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Risperidone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6917?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=risperidone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Risperidone: Patient drug information&quot;</a> and <a href=\"topic.htm?path=risperidone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Risperidone: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50629650\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Atypical Antipsychotics Safety Review</span>\n      <span class=\"collapsible-date\">September 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada has reviewed the potential risk of sleep walking and sleep-related eating disorder with the use of atypical antipsychotics and concluded there is a link between these adverse reactions and the use of these medications. Health Canada has recommended to update the product safety information for all atypical antipsychotics to include these adverse reactions.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/atypical-antipsychotics-assessing-potential-risk-sleep-walking-sleep-related-eating-disorder.html.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709402\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Increased mortality in elderly patients with dementia-related psychosis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in the drug-treated patients of between 1.6 and 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was approximately 4.5% compared with a rate of approximately 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Observational studies suggest that similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Risperidone is not approved for the treatment of patients with dementia-related psychosis.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218658\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>RisperDAL;</li>\n      <li>RisperDAL Consta;</li>\n      <li>RisperDAL M-TAB;</li>\n      <li>RisperiDONE M-TAB</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218659\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Risperdal;</li>\n      <li>Risperdal Consta;</li>\n      <li>Risperdal M-Tab</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218704\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antimanic Agent;</li>\n      <li>\n        Second Generation (Atypical) Antipsychotic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218663\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> When reinitiating treatment after discontinuation, the initial titration schedule should be followed. Limiting initial oral dose to 2 mg daily (in 1 or 2 divided doses) may reduce the risk of orthostatic hypotension/syncope.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bipolar mania (<b>monotherapy or as an adjunct to lithium or divalproex)</b>: </b> <i>Oral:</i> Initial: 2 to 3 mg once daily; if needed, adjust dose by 1 mg daily in intervals &ge;24 hours; dosing range: 1 to 6 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance: No dosing recommendation available for treatment &gt;3 weeks' duration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bipolar I maintenance (<b>monotherapy or as an adjunct to lithium or divalproex)</b>: </b> <i>IM (Risperdal Consta):</i> 25 mg every 2 weeks; if unresponsive, some may benefit from larger doses (37.5 to 50 mg); maximum dose: 50 mg every 2 weeks. Dosage adjustments should not be made more frequently than every 4 weeks. A lower initial dose of 12.5 mg may be appropriate in some patients (eg, hepatic or renal impairment, poor tolerability to other psychotropic medications).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Establishment of tolerability to oral risperidone is recommended prior to initiation of Risperdal Consta. Oral risperidone (or other antipsychotic) should be administered with the initial injection of Risperdal Consta and continued for 3 weeks (then discontinued) to maintain adequate therapeutic plasma concentrations prior to main release phase of risperidone from injection site.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Schizophrenia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral:</i> Initial: 2 mg daily in 1 to 2 divided doses; may be increased by 1 to 2 mg daily at intervals &ge;24 hours to a recommended dosage range of 4 to 8 mg daily. Daily dosages &gt;6 mg do not appear to confer any additional benefit, and the incidence of extrapyramidal symptoms is higher than with lower doses. Dose range studied in clinical trials: 4 to 16 mg daily. Maintenance: Recommended dosage range: 2 to 8 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IM (Risperdal Consta):</i> Initial: 25 mg every 2 weeks; if unresponsive, some may benefit from larger doses (37.5 to 50 mg); maximum dose: 50 mg every 2 weeks. No additional benefit was observed with doses &gt;50 mg; however, a higher incidence of adverse reactions was observed. Dosage adjustments should not be made more frequently than every 4 weeks. A lower initial dose of 12.5 mg may be appropriate in some patients (eg, demonstrated poor tolerability to other psychotropic medications).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Establishment of tolerability to oral risperidone is recommended prior to initiation of Risperdal Consta. Oral risperidone (or other antipsychotic) should be administered with the initial injection of Risperdal Consta and continued for 3 weeks (then discontinued) to maintain adequate therapeutic plasma concentrations prior to main release phase of risperidone from injection site.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Delusional infestation (also called delusional parasitosis) (off-label use): </b> <i>Oral: </i>Initial: 0.5 mg at bedtime; increase gradually based on response and tolerability up to 1 to 2 mg given at bedtime or in 2 divided doses. Doses up to 8 mg/day have been evaluated. (Freudenmann 2008; Heller 2013; Kenchaiah 2010). Additional data may be necessary to further define the role of risperidone in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Major depressive disorder (adjunct to antidepressants; off-label use): </b> <i>Oral: </i>Initial: 0.25 mg to 0.5 mg daily; slowly adjust dose based on response and tolerability up to 3 mg/day (Keitner 2009; Mahmoud 2007; Rapaport 2006; Reeves 2008). Average doses in clinical trials were 1.2 to 1.6 mg/day (Komossa 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Post-traumatic stress disorder (PTSD) (off-label use): </b> <i>Oral:</i> Initial: 0.5 to 1 mg at bedtime or 0.5 mg twice daily; may adjust dose based on response and tolerability to a maximum of 8 mg daily; total daily dose may be given in 2 or 3 divided doses. Average dose in clinical trials: 1.25 to 3.75 mg daily (Bandelow 2008; Bartzokis 2005; Hamner 2003; Padala 2006; Reich 2004; Rothbaum 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tourette syndrome (off-label use): </b> <i>Oral:</i> Initial: 0.25 mg once daily; increase gradually based on response and tolerability up to a usual dosage of 0.25 to 6 mg daily (Pringsheim 2012; Roessner 2011). Dosage adjustments in clinical trials were commonly in increments of &lt;0.5 mg twice daily and at intervals &ge;3 days (Bruggeman 2001; Dion 2002; Scahill 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Discontinuation of therapy:</b> American Psychiatric Association (APA), Canadian Psychiatric Association (CPA), and World Federation of Societies of Biological Psychiatry (WFSBP) guidelines recommend gradually tapering antipsychotics to avoid withdrawal symptoms and minimize the risk of relapse (APA [Lehman 2004]; Cerovecki 2013; CPA [Addington 2005]; WFSBP [Hasan 2012]); risk for withdrawal symptoms may be highest with highly anti-cholinergic or dopaminergic antipsychotics (Cerovecki 2013). When stopping antipsychotic therapy in patients with schizophrenia, the CPA guidelines recommend a gradual taper over 6 to 24 months, and the APA guidelines recommend reducing the dose by 10% each month (APA [Lehman 2004]; CPA [Addington 2005]). Continuing anti-parkinsonism agents for a brief period after discontinuation may prevent withdrawal symptoms (Cerovecki 2013). When switching antipsychotics, 3 strategies have been suggested: Cross-titration (gradually discontinuing the first antipsychotic while gradually increasing the new antipsychotic), overlap and taper (maintaining the dose of the first antipsychotic while gradually increasing the new antipsychotic, then tapering the first antipsychotic), and abrupt change (abruptly discontinuing the first antipsychotic and either increasing the new antipsychotic gradually or starting it at a treatment dose). Evidence supporting ideal switch strategies and taper rates is limited, and results are conflicting (Cerovecki 2013; Remington 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218683\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=risperidone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Risperidone: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> When reinitiating treatment after discontinuation, the initial titration schedule should be followed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bipolar mania (<b>monotherapy or as an adjunct to lithium or divalproex)</b>: </b> Children and Adolescents 10 to 17 years of age: <i>Oral:</i> Initial: 0.5 mg once daily; dose may be adjusted in increments of 0.5 to 1 mg daily at intervals &ge;24 hours to a dose of 1 to 2.5 mg daily. Doses ranging from 0.5 to 6 mg daily have been evaluated; however doses &gt;2.5 mg daily do not confer additional benefit and are associated with increased adverse events. Patients experiencing persistent somnolence may benefit from dividing the dosage into twice-daily doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance: No dosing recommendation available for treatment &gt;3 weeks' duration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Irritability associated with autistic disorder: </b> Children &ge;5 years of age and Adolescents: <i>Oral:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;15 kg: Use with caution; specific dosing recommendations not available</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">15 to &lt;20 kg: Initial: 0.25 mg daily; may increase dose to 0.5 mg daily after &ge;4 days, maintain dose for &ge;14 days. In patients not achieving sufficient clinical response, may increase dose by 0.25 mg daily in &ge;2-week intervals. Doses ranging from 0.5 to 3 mg daily have been evaluated. Following clinical response, consider gradually lowering dose. Patients experiencing persistent somnolence may benefit from a once-daily dose administered at bedtime, dividing the dosage into twice-daily doses, or a reduction of the dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;20 kg: Initial: 0.5 mg daily; may increase dose to 1 mg daily after &ge;4 days, maintain dose for &ge;14 days. In patients not achieving sufficient clinical response, may increase dose by 0.5 mg daily in &ge;2-week intervals. Doses ranging from 0.5 to 3 mg daily have been evaluated. Following clinical response, consider gradually lowering dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Schizophrenia:</b> Adolescents 13 to 17 years of age: <i>Oral:</i> Initial: 0.5 mg once daily; dose may be adjusted in increments of 0.5 to 1 mg daily at intervals &ge;24 hours to a dose of 3 mg daily. Doses ranging from 1 to 6 mg daily have been evaluated; however, doses &gt;3 mg daily do not confer additional benefit and are associated with increased adverse events. Patients experiencing persistent somnolence may benefit from dividing the dosage into twice-daily doses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tourette syndrome (off-label use):</b> Children and Adolescents: Initial: 0.125 to 0.5 mg once daily; increase gradually based on response and tolerability up to a usual dosage of 0.75 to 3 mg daily (AACAP [Murphy 2013]; Pringsheim 2012). Dosage adjustments in clinical trials were commonly in increments of &lt;0.5 mg twice daily and at intervals &ge;3 days; doses up to 4 mg daily have been evaluated in children and up to 6 mg daily in adolescents (Bruggeman 2001; Dion 2002; Ghanizadeh 2014; Gilbert 2004; Scahill 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218664\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bipolar mania (<b>monotherapy or as an adjunct to lithium or divalproex) and schizophrenia</b>: </b>Oral: Initial: 0.5 mg twice daily; titrate slowly. <b>Note:</b> Limiting initial dose to 1 mg daily (in 2 divided doses) may reduce the risk of orthostatic hypotension/syncope. Additional monitoring of renal function and orthostatic blood pressure may be warranted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bipolar I maintenance:</b> IM (Risperdal Consta): Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psychosis/agitation associated with dementia (off-label use): </b> Oral: Initial: 0.5 mg daily, in 1 to 2 divided doses; if necessary, gradually increase based on response and tolerability not to exceed 2 mg daily. Doses &gt;1 mg daily are associated with higher rates of extrapyramidal symptoms. In patients without a clinically significant response after 4 weeks, taper and withdraw therapy. In patients with an adequate response, attempt to taper and withdraw therapy within 4 months, unless symptoms recurred with a previous taper attempt. Assess symptoms at least monthly during taper and for at least 4 months after withdrawal of therapy (APA [Reus 2016]; Brodaty 2003; De Deyn 1999; Katz 1999; Schneider 2006; Sultzer 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218665\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: <b>Note:</b> Limiting initial dose to 1 mg daily (in 2 divided doses) may reduce the risk of orthostatic hypotension/syncope. Clearance may be decreased by 60% in patients with moderate to severe renal disease (CrCl &lt;60 mL/minute).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild or moderate impairment (CrCl &ge;30 mL/minute): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; reduce dosage.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe impairment (CrCl &lt;30 mL/minute): Initial: 0.5 mg twice daily; titrate slowly in increments of no more than 0.5 mg twice daily; increases to dosages &gt;1.5 mg twice daily should occur at intervals of &ge;1 week.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Initiate with <b>oral</b> dosing (0.5 mg twice daily for 1 week then 1 mg twice daily or 2 mg once daily for 1 week); if tolerated, begin 25 mg <b>IM</b> every 2 weeks; continue oral dosing for 3 weeks after the first IM injection. An initial IM dose of 12.5 mg may also be considered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218666\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: <b>Note:</b> Limiting initial doses to 1 mg daily (in 2 divided doses) may reduce the risk of orthostatic hypotension/syncope. The mean free fraction of risperidone in plasma may be increased by 35% in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild or moderate impairment (Child-Pugh class A or B): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; reduce dosage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment (Child-Pugh class C): Initial: 0.5 mg twice daily; titration should progress slowly in increments of no more than 0.5 mg twice daily; increases to dosages &gt;1.5 mg twice daily should occur at intervals of &ge;1 week.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Initiate with <b>oral</b> dosing (0.5 mg twice daily for 1 week then 1 mg twice daily or 2 mg once daily for 1 week); if tolerated, begin 25 mg <b>IM</b> every 2 weeks; continue oral dosing for 3 weeks after the first IM injection. An initial IM dose of 12.5 mg may also be considered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218631\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">RisperDAL: 1 mg/mL (30 mL) [contains benzoic acid]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">RisperDAL Consta: 12.5 mg (1 ea); 25 mg (1 ea); 37.5 mg (1 ea); 50 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">RisperDAL: 0.25 mg, 0.5 mg, 1 mg [contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">RisperDAL: 2 mg [contains corn starch, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">RisperDAL: 3 mg [contains corn starch, fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">RisperDAL: 4 mg [contains corn starch, fd&amp;c blue #2 aluminum lake, fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Disintegrating, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">RisperDAL M-TAB: 0.5 mg, 1 mg, 2 mg [DSC], 3 mg, 4 mg [contains aspartame, peppermint oil (mentha piperita oil)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">RisperiDONE M-TAB: 0.5 mg, 1 mg, 2 mg, 3 mg [DSC], 4 mg [DSC] [contains aspartame]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218617\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218635\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: May be administered without regard to meals.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral solution can be administered directly from the provided calibrated pipette or may be mixed with water, coffee, orange juice, or low-fat milk, but is <b>not compatible</b> with cola or tea.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Risperdal M-Tab should not be removed from blister pack until administered. Do not push tablet through foil (tablet may become damaged); peel back foil to expose tablet. Using dry hands, place immediately on tongue. Tablet will dissolve within seconds, and may be swallowed with or without liquid. Do not split or chew.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Shake syringe vigorously just before injection. Administer IM into either the deltoid muscle or the upper outer quadrant of the gluteal area. For IM use only; do not administer IV. Avoid  inadvertent injection into vasculature. Injection should alternate between the two arms or buttocks. Do not combine two different dosage strengths into one single administration. Do not substitute any components of the dose-pack; administer with needle provided (1-inch needle for deltoid administration or 2-inch needle for gluteal administration).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49133431\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration. For IM preparation, double gloves, a protective gown, and ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator) are recommended. Double gloving and a protective gown are required during IM administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218634\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Injection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bipolar disorder:</b> As monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Schizophrenia:</b> Treatment of schizophrenia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Oral:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bipolar mania: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Monotherapy:</i> For the treatment of acute manic or mixed episodes associated with bipolar I disorder in adults and in children and adolescents 10 to 17 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Adjunctive therapy:</i> As adjunctive therapy with lithium or valproate for the treatment of adults with acute manic or mixed episodes associated with bipolar I disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Irritability associated with autistic disorder:</b> For the treatment of irritability associated with autistic disorder in children and adolescents 5 to 17 years of age, including symptoms of aggression toward others, deliberate self-injuriousness, temper tantrums, and quickly changing moods.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Schizophrenia: </b>For the treatment of schizophrenia in adults and adolescents 13 to 17 years of age.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744895\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Delusional infestation (also called delusional parasitosis); Major depressive disorder; Post-traumatic stress disorder; Psychosis/agitation associated with dementia; Tourette syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218713\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">RisperiDONE may be confused with reserpine, rOPINIRole</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">RisperDAL may be confused with lisinopril, reserpine, Restoril</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Antipsychotics are identified in the Beers Criteria as potentially inappropriate medications to be avoided in patients 65 years and older with dementia due to an increased risk of mortality, cerebrovascular accidents (stroke), and a greater rate of cognitive decline with use; avoid antipsychotics for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. Use <i>may be appropriate</i> in geriatric patients with schizophrenia, bipolar disorder, or for short-term use as an antiemetic during chemotherapy. In addition, antipsychotics should be used with caution in older adults due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218624\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Sedation (children 12% to 63%; adults 5% to 11%), parkinsonian-like syndrome (children 6% to 62%; adults 8% to 25%), drowsiness (adults 5% to 41%; children 4% to 11%), insomnia (&le;32%), fatigue (children 18% to 31%; adults 1% to 9%), headache (12% to 21%), anxiety (&le;16%), dizziness (3% to 16%), drooling (children 12%; adults &lt;4%), akathisia (5% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight gain (&ge;7% kg increase from baseline: children 8% to 33%; adults 4% to 21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Increased appetite (children 4% to 44%; adults 4%), vomiting (children 10% to 20%; adults &lt;4%), constipation (5% to 17%), abdominal pain (children 6% to 16%; adults &lt;4%), nausea (5% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary incontinence (children 16%; adults &lt;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Tremor (adults &le;24%; children &le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (children 19%; adults &le;4%), cough (children &le;17%; adults &le;4%), rhinorrhea (children 12%; adults &lt;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (children 16%; adults 1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Bradycardia (&lt;4%), bundle branch block (&lt;4%), chest pain (&lt;4%), ECG changes (&lt;4%), facial edema (&lt;4%), first degree atrioventricular block (&lt;4%), hypotension (&lt;4%), orthostatic hypotension (&lt;4%), palpitations (&lt;4%), prolonged Q-T interval on ECG (&lt;4%), tachycardia (adults &lt;4%; children &lt;1%), hypertension (&le;3%), peripheral edema (&le;3%), syncope (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dystonia (2% to 6%), abnormal gait (4%), pain (1% to 4%), disturbance in attention (&le;4%), agitation (&lt;4%), ataxia (&lt;4%), depression (&lt;4%), disturbed sleep (&lt;4%), falling (&lt;4%), lethargy (&lt;4%), malaise (&lt;4%), nervousness (&lt;4%), orthostatic dizziness (&lt;4%), paresthesia (&lt;4%), seizure (&lt;4%), tardive dyskinesia (&lt;4%), vertigo (&lt;4%), hypoesthesia (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (&le;8%), eczema (&lt;4%), pruritus (&lt;4%), skin sclerosis (&lt;4%), xeroderma (&le;3%), acne vulgaris (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased thirst (children &le;7%; adults &lt;1%), weight loss (&le;4%), amenorrhea (4%), decreased libido (&lt;4%), galactorrhea (&lt;4%), glycosuria (&lt;4%), gynecomastia (&lt;4%), hyperglycemia (&lt;4%), hyperprolactinemia (&lt;4%), increased gamma-glutamyl transferase (&lt;4%), oligomenorrhea (&lt;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Xerostomia (&le;10%), dyspepsia (3% to 10%), sialorrhea (1% to 10%), diarrhea (&le;8%), decreased appetite (&le;6%), anorexia (&lt;4%), gastritis (&lt;4%), gastroenteritis (&lt;4%), toothache (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Menstruation (&le;4%), cystitis (&lt;4%), ejaculatory disorder (&lt;4%), erectile dysfunction (&lt;4%), irregular menses (&lt;4%), mastalgia (&lt;4%), sexual disorder (&lt;4%), urinary tract infection (&lt;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (&lt;4%), neutropenia (&lt;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (&lt;4%), increased serum AST (&lt;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (&lt;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (&lt;4%), influenza (&lt;4%), localized infection (&lt;4%), subcutaneous abscess (&lt;4%), viral infection (&lt;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Induration at injection site (&lt;4%), injection site reaction (&lt;4%), local pain (buttock: &lt;4%), pain at injection site (&lt;4%), swelling at injection site (&lt;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Limb pain (2% to 6%), dyskinesia (adults &le;6%; children &lt;1%), back pain (&le;4%), arthralgia (2% to 4%), abnormal posture (&lt;4%), akinesia (&lt;4%), hypokinesia (&lt;4%), musculoskeletal chest pain (&lt;4%), myalgia (&lt;4%), neck pain (&lt;4%), weakness (&lt;4%), increased creatine phosphokinase (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision (2% to 7%), conjunctivitis (&lt;4%), reduced visual acuity (&lt;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otalgia (&le;4%), otic infection (&lt;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasal congestion (&le;10%), pharyngolaryngeal pain (3% to 10%), rhinitis (&le;9%), respiratory tract infection (&le;8%), bronchitis (&lt;4%), dyspnea (&lt;4%), flu-like symptoms (&lt;4%), pharyngitis (&lt;4%), pneumonia (&lt;4%), sinusitis (&lt;4%), epistaxis (&le;2%), sinus congestion (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal erythrocytes, abscess at injection site, acariasis, agranulocytosis, alopecia, anaphylaxis, angioedema, anorgasmia, apnea, aspiration, atrial fibrillation, atrial premature contractions, blepharospasm, blunted affect, breast hypertrophy, bronchopneumonia, cellulitis, cerebral ischemia, cerebrovascular accident, cerebrovascular disease, cheilitis, chills, cholestatic hepatitis, cholinergic syndrome, cold extremities, coma, confusion, crusting of eyelid, cutaneous nodule, cyst, decreased hematocrit, decreased hemoglobin, dehydration, delirium, depression of ST segment on ECG, dermal ulcer, dermatological disease, desquamation, diabetes mellitus, diabetic coma, diabetic ketoacidosis, disruption of body temperature regulation, diverticulitis, dry eye syndrome, dysgeusia, dysphagia, dysuria, edema, eosinophilia, erythema, esophageal motility disorder, esophagitis, eye discharge, eye infection, eyelid edema, fecal incontinence, fecaloma, feeling abnormal, flushing, glaucoma, granulocytopenia, hematemesis, hematoma, hematuria, hemorrhage, hepatic failure, hepatic injury, hyperkeratosis, hyperphosphatemia, hyperthermia, hypertonia, hypertriglyceridemia, hyperuricemia, hyperventilation, hypoglycemia, hypokalemia, hyponatremia, hypoproteinemia, hypothermia, impaired consciousness, increased serum cholesterol, increased serum transaminases, intestinal obstruction, intraoperative floppy iris syndrome, inversion T wave on ECG, jaundice, joint stiffness, joint swelling, lacrimation, leukocytosis, leukopenia, leukorrhea, lip edema, loss of balance, lower respiratory tract infection, lymphadenopathy, mania, mastitis, migraine, movement disorder, myocardial infarction, myocarditis, nasal mucosa swelling, neuroleptic malignant syndrome, nystagmus, oculogyric crisis, ocular hyperemia, onychomycosis, pancreatitis, Pelger-Huet anomaly, phlebitis, photophobia, pitting edema, pituitary neoplasm, pollakiuria, polydipsia, precocious puberty, priapism, pulmonary congestion, pulmonary embolism, rales, renal insufficiency, respiratory congestion, respiratory distress, retinal artery occlusion, retrograde ejaculation, rhabdomyolysis, rigors, sarcoidosis, seborrhea, seborrheic dermatitis of scalp, SIADH, skin discoloration, skin lesion, sleep apnea, speech disturbance, stomatitis, stridor, swelling of eye, synostosis, thrombocytopenia, thrombophlebitis, thrombotic thrombocytopenic purpura, tinnitus, tissue necrosis, tongue discoloration, tongue edema, tongue paralysis, tongue spasm, tonsillitis, torticollis, tracheobronchitis, transient ischemic attacks, unresponsive to stimuli, urinary retention, urticaria, vaginal discharge, ventricular premature contractions, ventricular tachycardia, voice disorder, water intoxication, wheezing, withdrawal syndrome, xerophthalmia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218638\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to risperidone, paliperidone, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218621\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered cardiac conduction: May alter cardiac conduction; life-threatening arrhythmias have occurred with therapeutic doses of antipsychotics. Use caution with history of conduction abnormalities. Relative to other neuroleptics, risperidone has a low risk of arrhythmias (APA [Lehman 2004]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticholinergic effects: May cause anticholinergic effects (confusion, agitation, constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, urinary retention, BPH, xerostomia, or visual problems. Relative to other neuroleptics, risperidone has a low potency of cholinergic blockade (Richelson 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antiemetic effects: May mask toxicity of other drugs or conditions (eg, intestinal obstruction, Reyes syndrome, brain tumor) due to antiemetic effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood dyscrasias: Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko-/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1,000/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebrovascular effects: An increased incidence of cerebrovascular effects (eg, transient ischemic attack, stroke), including fatalities, has been reported in placebo-controlled trials of risperidone for the unapproved use in elderly patients with dementia-related psychosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving). May be low to moderately sedating in comparison with other antipsychotics (Richelson 1999); dose-related effects have been observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dyslipidemia: Has been reported with atypical antipsychotics; risk profile may differ between agents. Discrepant results have been reported in clinical trials, regarding lipid changes associated with risperidone (American Diabetes Association, 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of pneumonia (eg, Alzheimer disease).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extrapyramidal symptoms: May cause extrapyramidal symptoms (EPS), including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (risk of these reactions is generally much lower relative to typical/conventional antipsychotics; frequencies reported are similar to placebo). Risk of dystonia (and possibly other EPS) may be greater with increased doses, use of conventional antipsychotics, males, and younger patients. Factors associated with greater vulnerability to tardive dyskinesia include older in age, female gender combined with postmenopausal status, Parkinson disease, pseudoparkinsonism symptoms, affective disorders (particularly major depressive disorder), concurrent medical diseases such as diabetes, previous brain damage, alcoholism, poor treatment response, and use of high doses of antipsychotics (APA [Lehman 2004]; Soares-Weiser 2007). Consider therapy discontinuation with signs/symptoms of tardive dyskinesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Falls: May increase the risk for falls due to somnolence, orthostatic hypotension, and motor or sensory instability. Complete fall risk assessments at baseline and periodically during treatment in patients with diseases or on medications that may also increase fall risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperglycemia: Atypical antipsychotics have been associated with development of hyperglycemia; in some cases, may be extreme and associated with ketoacidosis, hyperosmolar coma, or death. Use with caution in patients with diabetes or other disorders of glucose regulation; monitor for worsening of glucose control.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperprolactinemia: Risperidone is associated with greater increases in prolactin levels as compared to other antipsychotic agents; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown. Risk factors for hyperprolactinemia in patients taking risperidone include female gender, younger age at onset of illness, and higher scores on the Positive and Negative Symptom Scale (PANSS). Additionally, higher doses are associated with greater elevations in prolactin concentrations (Bo 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions including anaphylactic reactions and angioedema have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intraoperative floppy iris syndrome: Few case reports describe intraoperative floppy iris syndrome (IFIS) in patients receiving risperidone and undergoing cataract surgery (Ford 2011). Prior to cataract surgery, evaluate for prior or current risperidone use. The benefits or risks of interrupting risperidone prior to surgery have not been established; clinicians are advised to proceed with surgery cautiously.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuroleptic malignant syndrome (NMS): Use may be associated with neuroleptic malignant syndrome (NMS); monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect (eg, concurrent medication use which may predispose to hypotension/bradycardia or presence of hypovolemia) or in those who would not tolerate transient hypotensive episodes. Use caution with history of cerebrovascular or cardiovascular disease (MI, heart failure, or ischemic disease).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Priapism: Rare cases of priapism have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal ideation: The possibility of a suicide attempt is inherent in psychotic illness or bipolar disorder; use with caution in high-risk patients during initiation of therapy. Prescriptions should be written for the smallest quantity consistent with good patient care.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects (Kwok 2005, Martinez 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Weight gain: Significant weight gain has been observed with antipsychotic therapy; incidence varies with product. Monitor waist circumference and BMI.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with severe cardiac disease, hemodynamic instability, prior myocardial infarction or ischemic heart disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dementia: <b>[US Boxed Warning]: Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo.</b> Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Use with caution in patients with Lewy body dementia or Parkinson disease dementia due to greater risk of adverse effects, increased sensitivity to extrapyramidal effects, and association with irreversible cognitive decompensation or death. (APA [Reus 2016]). Risperidone is not approved for the treatment of dementia-releated psychosis. Careful assessment of risk factors for stroke or existing cardiovascular morbidities is required prior to initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic disease or impairment; dosage reduction is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Parkinson disease: Use with caution in patients with Parkinson disease; antipsychotics may aggravate the motor disturbances of Parkinson disease (APA [Lehman 2004]; APA [Reus 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal disease; dosage reduction is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dispersible tablet: Inform patients with phenylketonuria that dispersible tablets contain phenylalanine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injectable suspension: Vehicle used (polylactide-co-glycolide microspheres) has rarely been associated with retinal artery occlusion in patients with abnormal arteriovenous anastomosis (eg, patent foramen ovale). Not for IV use; administer only as an intramuscular injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>\n          <b>Other warnings/precautions</b>:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy<b>: </b>When discontinuing antipsychotic therapy, the American Psychiatric Association (APA), Canadian Psychiatric Association (CPA), and World Federation of Societies of Biological Psychiatry (WFSBP) guidelines recommend gradually tapering antipsychotics to avoid physical withdrawal symptoms, including anorexia, anxiety, diaphoresis, diarrhea, dizziness, dyskinesia, headache, myalgia, nausea, paresthesia, restlessness, tremulousness, and vomiting (APA [Lehman 2004]; CPA [Addington 2005]; Lambert 2007; WFSBP [Hasan 2012]). The risk of withdrawal symptoms is highest following abrupt discontinuation of highly anti-cholinergic or dopaminergic antipsychotics (Cerovecki 2013). Additional factors such as duration of antipsychotic exposure, the indication for use, medication half-life, and risk for relapse should be considered. In schizophrenia, there is no reliable indicator to differentiate the minority who will not from the majority who will relapse with drug discontinuation. However, studies in which the medication of well-stabilized patients were discontinued indicate that 75% of patients relapse within 6 to 24 months. Indefinite maintenance antipsychotic medication is generally recommended, and especially for patients who have had multiple prior episodes or 2 episodes within 5 years (APA [Lehman 2004]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218697\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2D6 (major), CYP3A4 (minor), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218625\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9868&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May diminish the anticholinergic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Amifampridine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amisulpride: Antipsychotic Agents may enhance the adverse/toxic effect of Amisulpride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: Antipsychotic Agents may diminish the stimulatory effect of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-Parkinson Agents (Dopamine Agonist): Antipsychotic Agents (Second Generation [Atypical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).  Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of RisperiDONE. Management: Consider increasing the dose of risperidone (to no more than double the original dose) if carbamazepine is initiated/dose increased. Monitor for reduced therapeutic effects of risperidone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: Antipsychotic Agents may diminish the therapeutic effect of Guanethidine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: May enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May enhance the adverse/toxic effect of RisperiDONE. Management: Consider alternative diuretic therapy (e.g., thiazides) to more potent diuretics (e.g., furosemide) in elderly patients receiving risperidone. Patients who require use of more potent diuretic therapy should be closely monitored and adequately hydrated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mequitazine: Antipsychotic Agents may enhance the arrhythmogenic effect of Mequitazine.  Management: Consider alternatives to one of these agents when possible.  While this combination is not specifically contraindicated, mequitazine labeling describes this combination as discouraged.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: Antipsychotic Agents may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paliperidone: RisperiDONE may enhance the adverse/toxic effect of Paliperidone.  Management: Additive paliperidone exposure is expected with this combination.  Consider using an alternative combination when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of sensitive CYP2D6 substrates when possible, particularly those substrates with a narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Substrates (High risk with Inhibitors) may increase the serum concentration of Perhexiline. Perhexiline may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: Antipsychotic Agents may diminish the therapeutic effect of Piribedil. Piribedil may diminish the therapeutic effect of Antipsychotic Agents.  Management: Use of piribedil with antiemetic neuroleptics is contraindicated, and use with antipsychotic neuroleptics, except for clozapine, is not recommended.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: Antipsychotic Agents may diminish the therapeutic effect of Quinagolide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of RisperiDONE.<b> Exceptions: </b>FluvoxaMINE.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulpiride: Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: May enhance the adverse/toxic effect of RisperiDONE. Generalized edema has developed.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verapamil: May increase the serum concentration of RisperiDONE.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218655\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Oral solution is not compatible with beverages containing tannin or pectinate (cola or tea). Management: Administer oral solution with water, coffee, orange juice, or low-fat milk.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218627\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2888768\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. In human studies, risperidone and its metabolite cross the placenta (Newport 2007). Agenesis of the corpus callosum has been noted in one case report of an infant exposed to risperidone in utero; relationship to risperidone exposure is not known. Antipsychotic use during the third trimester of pregnancy has a risk for extrapyramidal symptoms (EPS) and/or withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor. These effects may be self-limiting and allow recovery within hours or days with no specific treatment, or they may be severe requiring prolonged hospitalization.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When using Risperdal Consta, patients should notify health care provider if they become or intend to become pregnant during therapy or within 12 weeks of last injection.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The ACOG recommends that therapy during pregnancy be individualized; treatment with psychiatric medications during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary health care provider, and pediatrician. Safety data related to atypical antipsychotics during pregnancy is limited. As a result, routine use is not recommended. However, if a woman is inadvertently exposed to an atypical antipsychotic while pregnant, continuing therapy may be preferable to switching to an agent that the fetus has not yet been exposed to; consider risk:benefit (ACOG 2008). If treatment is needed in a woman planning a pregnancy or if treatment is initiated during pregnancy, use of an agent other than risperidol is preferred (Larsen 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Risperidone may cause hyperprolactinemia, which may decrease reproductive function in both males and females.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Healthcare providers are encouraged to enroll women 18 to 45 years of age exposed to risperidone during pregnancy in the Atypical Antipsychotics Pregnancy Registry (1-866-961-2388 or http://www.womensmentalhealth.org/pregnancyregistry).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218642\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Risperidone and its active metabolite, 9-hydroxyrisperidone, are present in breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of risperidone is 1.5% and the RID of 9-hydroxyrisperidone is 5.5% when calculated using the highest breast milk concentration located and compared to a weight-adjusted maternal dose of 2 mg/day.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000). However, some sources note breastfeeding should only be considered if the RID is &lt;5% for psychotropic agents (Larsen 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The RID of risperidone was calculated using a milk concentration of 3 ng/mL, providing an estimated daily infant dose via breast milk of 0.45 mcg/kg/day. The RID of 9-hydroxyrisperidone was calculated using a milk concentration of 11 ng/mL, providing an estimated daily infant dose via breast milk of 1.65 mcg/kg/day. These milk concentrations were obtained following maternal administration of oral risperidone 2 mg/day, with sampling occurring 3 hours after the maternal dose following 6 days of therapy; treatment started 1 week postpartum (Aichhorn 2005). Peak milk concentrations appear to be within 2 to 4 hours after an oral maternal dose (Aichhorn 2005; Hill 2000; Ilett 2004).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, infants exposed to second generation antipsychotics via breast milk should be monitored weekly for the first month of exposure for symptoms, such as appetite changes, insomnia, irritability, or lethargy (Uguz 2016). Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother. It is also recommended that women using Risperdal Consta not breastfeed during therapy or for 12 weeks after the last injection. Based on available information, use of agents other than risperidone in breastfeeding women is preferred (Larsen 2015; Pacchiarotti 2016; Uguz 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218643\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May be taken without regard to meals. Dispersible tablets contain phenylalanine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218629\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Mental status; vital signs (as clinically indicated); blood pressure (baseline; repeat 3 months after antipsychotic initiation, then yearly); weight, height, BMI, waist circumference (baseline; repeat at 4, 8, and 12 weeks after initiating or changing therapy, then quarterly; consider switching to a different antipsychotic for a weight gain &ge;5% of initial weight); CBC (as clinically indicated; monitor frequently during the first few months of therapy in patients with pre-existing low WBC or history of drug-induced leukopenia/neutropenia); electrolytes, renal and liver function (annually and as clinically indicated); personal and family history of obesity, diabetes, dyslipidemia, hypertension, or cardiovascular disease (baseline; repeat annually); fasting plasma glucose level/HbA<sub>1c</sub> (baseline; repeat 3 months after starting antipsychotic, then yearly); fasting lipid panel (baseline; repeat 3 months after initiation of antipsychotic; if LDL level is normal repeat at 2 to 5 year intervals or more frequently if clinical indicated); changes in menstruation, libido, development of galactorrhea, erectile and ejaculatory function (at each visit for the first 12 weeks after the antipsychotic is initiated or until the dose is stable, then yearly); abnormal involuntary movements or parkinsonian signs (baseline; repeat weekly until dose stabilized for at least 2 weeks after introduction and for 2 weeks after any significant dose increase); tardive dyskinesia (every 12 months; high-risk patients every 6 months); ocular examination (yearly in patients &gt;40 years; every 2 years in younger patients) (ADA, 2004; Lehman, 2004; Marder, 2004).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218620\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Risperidone is a benzisoxazole atypical antipsychotic with high 5-HT<sub>2</sub>- dopamine-D<sub>2</sub> receptor antagonist activity. Alpha<sub>1</sub>, alpha<sub>2</sub> adrenergic, and histaminergic receptors are also antagonized with high affinity. Risperidone has low to moderate affinity for 5-HT<sub>1C</sub>, 5-HT<sub>1D</sub>, and 5-HT<sub>1A</sub> receptors, weak affinity for D<sub>1</sub> and no affinity for muscarinics or beta<sub>1</sub> and beta<sub>2</sub> receptors.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218637\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: </b>Following oral administration, the pharmacokinetics of risperidone and 9-hydroxyrisperidone in children were found to be similar to values in adults (after adjusting for differences in body weight).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Rapid and well absorbed; food does not affect rate or extent</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Injection: &lt;1% absorbed initially; main release occurs at ~3 weeks and is maintained from 4 to 6 weeks; release ends by 7 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 1 to 2 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding, plasma: Risperidone 90%; 9-hydroxyrisperidone: 77%; <b>Note: </b>Risperidone free fraction may be increased by ~35% in patients with hepatic impairment due to decreased concentrations of albumin and alpha-1 acid glycoprotein</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensively hepatic via CYP2D6 to 9-hydroxyrisperidone (similar pharmacological activity as risperidone); <i>N</i>-dealkylation is a second minor pathway; <b>Note:</b> 9-hydroxyrisperidone is the predominant circulating form and is approximately equal to risperidone in receptor binding activity; clinical effects are from combined concentrations of risperidone and 9-hydroxyrisperidone; clinically important differences between CYP2D6 poor and extensive metabolizers are not expected (pharmacokinetics of the sum of risperidone and 9-hydroxyrisperidone were similar in poor and extensive metabolizers)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 70%; Tablet (relative to solution): 94%; orally-disintegrating tablets and oral solution are bioequivalent to tablets</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Injection: Deltoid IM injection is bioequivalent to gluteal IM injection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Active moiety (risperidone and its active metabolite 9-hydroxyrisperidone):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 20 hours (mean); prolonged in elderly patients</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extensive metabolizers: Risperidone: 3 hours; 9-hydroxyrisperidone: 21 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Poor metabolizers: Risperidone: 20 hours; 9-hydroxyrisperidone: 30 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Injection: 3 to 6 days; related to microsphere erosion and subsequent absorption of risperidone</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Oral: Risperidone: Within 1 hour; 9-hydroxyrisperidone: Extensive metabolizers: 3 hours; Poor metabolizers: 17 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (70%); feces (14%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218641\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (RisperDAL Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (30 mL): $430.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (RisperiDONE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (30 mL): $152.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (RisperDAL Consta Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg (1): $272.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (1): $544.15</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">37.5 mg (1): $816.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $1,088.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (RisperDAL M-TAB Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (28): $353.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (28): $413.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (28): $847.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (28): $1,138.61</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (RisperiDONE M-TAB Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (28): $131.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (28): $154.07</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (28): $250.49</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (RisperiDONE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg (1): $4.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (30): $147.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (28): $154.07</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (28): $250.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (28): $316.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (28): $424.45</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (RisperDAL Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg (100): $1,101.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (100): $1,208.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $1,285.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $2,147.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (100): $2,522.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (60): $2,033.21</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (RisperiDONE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg (60): $234.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (60): $256.31</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (60): $273.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (60): $456.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (60): $535.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (60): $720.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218644\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aleptolan (LV);</li>\n      <li>Anxilet (TW);</li>\n      <li>Arketin (ES);</li>\n      <li>Aspidon (PH);</li>\n      <li>Calmapride (ES);</li>\n      <li>Diaforin (ES);</li>\n      <li>Dyperidone (PH);</li>\n      <li>Eperon (SG);</li>\n      <li>Eridon (UA);</li>\n      <li>Goval (EC);</li>\n      <li>Ispidon (PE);</li>\n      <li>Luvenil (PY);</li>\n      <li>Mirabril (PY);</li>\n      <li>Neorisp (BG);</li>\n      <li>Neripros (ID);</li>\n      <li>Neuris (TH);</li>\n      <li>Nodiril (MT);</li>\n      <li>Noprenia (ID);</li>\n      <li>Noprenia OS (ID);</li>\n      <li>Ozidal (AU);</li>\n      <li>Perdamel (IE, MT);</li>\n      <li>Persidal-2 (ID);</li>\n      <li>Prospera (HR);</li>\n      <li>Raxidone (QA);</li>\n      <li>Renuvie (PH);</li>\n      <li>Resdone (AU);</li>\n      <li>Respal (LB, QA);</li>\n      <li>Resperiteg (NI);</li>\n      <li>Revoc (LK);</li>\n      <li>Riatul (EC);</li>\n      <li>Ridal (NZ, SG);</li>\n      <li>Ridkline (MY);</li>\n      <li>Rileptid (HK, RO, VN);</li>\n      <li>Riper (TW);</li>\n      <li>Riperidon (KR);</li>\n      <li>Riscord (LK);</li>\n      <li>Risdin (PH);</li>\n      <li>Risdon (TW);</li>\n      <li>Risfree (KR);</li>\n      <li>Risnia (HR);</li>\n      <li>Rison (RO);</li>\n      <li>Risoperin (KR);</li>\n      <li>Rispa (AU);</li>\n      <li>Rispaxol (LV);</li>\n      <li>Rispefar (SG);</li>\n      <li>Risperdal (AE, AR, AT, AU, BB, BD, BE, BF, BH, BJ, BO, BR, CH, CI, CL, CN, CO, CY, CZ, DE, DK, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, ID, IE, IL, IQ, IR, IS, IT, JO, JP, KE, KR, KW, LB, LK, LR, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NO, NZ, OM, PE, PH, PK, PT, QA, SA, SC, SD, SE, SG, SI, SK, SL, SN, SY, TH, TN, TR, TW, TZ, UG, UY, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Risperdal Const (BM, BS, BZ, GY, JM, NL, PR, SR, TT);</li>\n      <li>Risperdal Consta (AE, AU, BB, BH, CH, CN, CY, DE, EC, ES, GB, HK, ID, IE, IL, IS, JO, KR, KW, LB, MT, MY, NO, NZ, PE, PH, QA, SA, SE, SG, SI, SK, TH, TW);</li>\n      <li>Risperdal OD (JP);</li>\n      <li>Risperdal Quicklet (AU, BM, BS, BZ, DE, GB, GY, HK, IE, JM, NL, NZ, PH, PR, SG, SI, SR, TH, TT);</li>\n      <li>Risperdalconsta LP (FR);</li>\n      <li>Risperidex (IL);</li>\n      <li>Risperigamma (HK);</li>\n      <li>Risperiteg (CR, DO, GT, HN, PA, SV);</li>\n      <li>Risperon (NZ, VN);</li>\n      <li>Rispeva (IE);</li>\n      <li>Rispid (IN);</li>\n      <li>Rispolept (LV, RU);</li>\n      <li>Rispolet (EE);</li>\n      <li>Rispond (IL, LK, PH);</li>\n      <li>Rispone (IE);</li>\n      <li>Rispons (HK);</li>\n      <li>Risset (HR);</li>\n      <li>Rixadone (AU);</li>\n      <li>Ryspolept (UA);</li>\n      <li>Rysset (UA);</li>\n      <li>Saxid (QA);</li>\n      <li>Sequinan (AR);</li>\n      <li>Spiron (EC);</li>\n      <li>Steviso (PH);</li>\n      <li>Torendo (BG, UA);</li>\n      <li>Xenoma (RO);</li>\n      <li>Zofredal (ID);</li>\n      <li>Zyresp (VN);</li>\n      <li>&Ntilde;orispez (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aichhorn W, Stuppaeck C, Whitworth AB. Risperidone and breast-feeding. <i>J Psychopharmacol</i>. 2005;19(2):211-213.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/15728443/pubmed\" target=\"_blank\" id=\"15728443\">15728443</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists, ACOG Practice Bulletin: Clinical Management Guidelines for Obstetricians-Gynecologists No. 92 April 2008 (Replaces Practice Bulletin Number 87, November 2007), &ldquo;Use of Psychiatric Medications During Pregnancy and Lactation,&rdquo; <i>Obstet Gynecol</i>, 2008, 111(4):1001-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/18378767/pubmed\" target=\"_blank\" id=\"18378767\">18378767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity, &ldquo;Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes,&rdquo; <i>Obes Res</i>, 2004, 12(2):362-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/14981231/pubmed\" target=\"_blank\" id=\"14981231\">14981231</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc.</i> 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB, Lane JR, et al, &ldquo;Hydrocodone Excretion Into Breast Milk: The First Two Reported Cases,&rdquo; <i>Breastfeed Med</i>, 2007, 2(1):10-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/17661614/pubmed\" target=\"_blank\" id=\"17661614\">17661614</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bandelow B, Zohar J, Hollander E, et al, &ldquo;World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders -- First Revision,&rdquo; <i>World J Biol Psychiatry</i>, 2008, 9(4): 248-312.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/18949648/pubmed\" target=\"_blank\" id=\"18949648\">18949648</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15737661\"></a>Bartzokis G, Lu PH, Turner J, Mintz J, Saunders CS. Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. <i>Biol Psychiatry</i>. 2005;57(5):474-479.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/15737661/pubmed\" target=\"_blank\" id=\"15737661\">15737661</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benedek DM, Friedman MJ, Zatzick D, et al, &ldquo;Guideline Watch (March 2009): Practice Guideline for the Treatment of Patients With Acute Stress Disorder and Posttraumatic Stress Disorder.&rdquo;</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27829454\"></a>Bo Q, Dong F, Li X, Wang Z, Ma X, Wang C. Prolactin related symptoms during risperidone maintenance treatment: results from a prospective, multicenter study of schizophrenia. <i>BMC Psychiatry</i>. 2016;16(1):386. doi: 10.1186/s12888-016-1103-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/27829454/pubmed\" target=\"_blank\" id=\"27829454\">27829454</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12633121\"></a>Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, Lee E, Lyons B, Grossman F. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. <i>J Clin Psychiatry</i>. 2003;64:134&ndash;143.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/12633121/pubmed\" target=\"_blank\" id=\"12633121\">12633121</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11235929\"></a>Bruggeman R, van der Linden C, Buitelaar JK, et al. Risperidone Versus Pimozide in Tourette's Disorder: A Comparative Double-Blind Parallel-Group Study. <i>J Clin Psychiatry</i>. 2001;62(1):50-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/11235929/pubmed\" target=\"_blank\" id=\"11235929\">11235929</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canadian Psychiatric Association. Clinical practice guidelines. Treatment of schizophrenia. <i>Can J Psychiatry</i>. 2005;50(13)(suppl 1):7S-57S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/16529334/pubmed\" target=\"_blank\" id=\"16529334\">16529334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. <i>CNS Drugs</i>. 2013;27(7):545-572. doi: 10.1007/s40263-013-0079-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/23821039/pubmed\" target=\"_blank\" id=\"23821039\">23821039</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coppola D, Russo LJ, Kwarta RF Jr, et al, &quot;Evaluating the Postmarketing Experience of Risperidone Use During Pregnancy: Pregnancy and Neonatal Outcomes,&quot; <i>Drug Saf,</i> 2007, 30(3):247-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/17343431/pubmed\" target=\"_blank\" id=\"17343431\">17343431</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10496251\"></a>De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, Eriksson S, Lawlor BA: A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. <i>Neurology</i>. 1999;53:946&ndash;955.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/10496251/pubmed\" target=\"_blank\" id=\"10496251\">10496251</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11799340\"></a>Dion Y, Annable L, Sandor P, et al, &ldquo;Risperidone in the Treatment of Tourette Syndrome: A Double-Blind, Placebo-Controlled Trial,&rdquo; <i>J Clin Psychopharmacol</i>, 2002, 22(1):31-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/11799340/pubmed\" target=\"_blank\" id=\"11799340\">11799340</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ford RL, Sallam A, Towler HM. Intraoperative floppy iris syndrome associated with risperidone intake. <i>Eur J Ophthalmol</i>. 2011;21(2):210-211.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/20853271/pubmed\" target=\"_blank\" id=\"20853271\">20853271</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Freudenmann RW, Lepping P. Second-generation antipsychotics in primary and secondary delusional parasitosis: outcome and efficacy. <i>J Clin Psychopharmacol</i>. 2008;28(5):500-508.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11886028\"></a>Gaffney GR, Perry PJ, Lund BC, Bever-Stille KA, Arndt S, Kuperman S. Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. <i>J Am Acad Child Adolesc Psychiatry</i>. 2002;41(3):330-336.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/11886028/pubmed\" target=\"_blank\" id=\"11886028\">11886028</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24343476\"></a>Ghanizadeh A, Haghighi A. Aripiprazole versus risperidone for treating children and adolescents with tic disorder: a randomized double blind clinical trial. <i>Child Psychiatry Hum Dev</i>. 2014;45(5):596-603.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/24343476/pubmed\" target=\"_blank\" id=\"24343476\">24343476</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14726728\"></a>Gilbert DL, Batterson JR, Sethuraman G, Sallee FR. Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. <i>J Am Acad Child Adolesc Psychiatry</i>. 2004;43(2):206-214.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/14726728/pubmed\" target=\"_blank\" id=\"14726728\">14726728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12490768\"></a>Hamner MB, Faldowski RA, Ulmer HG, Frueh BC, Huber MG, Arana GW. Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. <i>Int Clin Psychopharmacol</i>. 2003;18(1):1-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/12490768/pubmed\" target=\"_blank\" id=\"12490768\">12490768</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hasan A, Falkai P, Wobrock T, et al; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. <i>World J Biol Psychiatry</i>. 2012;13(5):318-378. doi: 10.3109/15622975.2012.696143.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/22834451/pubmed\" target=\"_blank\" id=\"22834451\">22834451</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heller MM; Wong JW; Lee ES; Ladizinski B; Grau M; Howard JL; Berger TG; Koo JY; Murase JE. Delusional infestations: clinical presentation, diagnosis and treatment. [Review]. <i>International Journal of Dermatology</i>. 2013;52(7):775-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/23789596/pubmed\" target=\"_blank\" id=\"23789596\">23789596</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hill RC, McIvor RJ, Wojnar-Horton RE, Hackett LP, Ilett KF. Risperidone distribution and excretion into human milk: case report and estimated infant exposure during breast-feeding. <i>J Clin Psychopharmacol</i>. 2000;20(2):285-286.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/10770482/pubmed\" target=\"_blank\" id=\"10770482\">10770482</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ilett KF, Hackett LP, Kristensen JH, Vaddadi KS, Gardiner SJ, Begg EJ. Transfer of risperidone and 9-hydroxyrisperidone into human milk. <i>Ann Pharmacother.</i> 2004;38(2):273-276.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/14742766/pubmed\" target=\"_blank\" id=\"14742766\">14742766</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10084637\"></a>Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. <i>J Clin Psychiatry</i>. 1999;60:107&ndash;115.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/10084637/pubmed\" target=\"_blank\" id=\"10084637\">10084637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keitner GI, Garlow SJ, Ryan CE, Ninan PT, Solomon DA, et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. <i>J Psychiatr Res</i>. 2009;43(3):205-214. doi: 10.1016/j.jpsychires.2008.05.003. Epub 2008 Jun 30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/18586273/pubmed\" target=\"_blank\" id=\"18586273\">18586273</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kenchaiah BK, Kumar S, Tharyan P. Atypical anti-psychotics in delusional parasitosis: a retrospective case series of 20 patients. <i>Int J Dermatol</i>. 2010;49(1):95-100.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21154393\"></a>Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S. Second-generation antipsychotics for major depressive disorder and dysthymia. <i>Cochrane Database Syst Rev</i>. 2010;(12):CD008121. doi: 10.1002/14651858.CD008121.pub2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/21154393/pubmed\" target=\"_blank\" id=\"21154393\">21154393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kwok JS, Chan TY. Recurrent heat-related illnesses during antipsychotic treatment. <i>Ann Pharmacother</i>. 2005;39(11):1940-1942.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/16174785/pubmed\" target=\"_blank\" id=\"16174785\">16174785</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. <i>J Clin Psychiatry</i>. 2007;68(suppl 6):10-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/17650054/pubmed\" target=\"_blank\" id=\"17650054\">17650054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/26344706/pubmed\" target=\"_blank\" id=\"26344706\">26344706</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. <i>Am J Psychiatry</i>. 2004;161(2)(suppl):1-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/15000267/pubmed\" target=\"_blank\" id=\"15000267\">15000267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahmoud RA, Pandina GJ, Turkoz I, Kosik-Gonzalez C, Canuso CM, et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. <i>Ann Intern Med</i>. 2007;147(9):593-602.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/17975181/pubmed\" target=\"_blank\" id=\"17975181\">17975181</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. <i>Am J Psychiatry</i>. 2004;161(8):1334-1349.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/15285957/pubmed\" target=\"_blank\" id=\"15285957\">15285957</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martinez M, Devenport L, Saussy J, Martinez J. Drug-associated heat stroke. <i>South Med J</i>. 2002;95(8):799-802.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/12190212/pubmed\" target=\"_blank\" id=\"12190212\">12190212</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murphy TK, Lewin AB, Storch EA, Stock S, et al. Practice parameter for the assessment and treatment of children and adolescents with tic disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2013;52(12):1341-1359.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/24290467/pubmed\" target=\"_blank\" id=\"24290467\">24290467</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health , &ldquo;Schizophrenia. Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Updated),&rdquo; National Clinical Practice Guideline Number 82, 2009:1-399. Available at www.nice.org.uk/cg082</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19687129\"></a>Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. <i>Am J Psychiatry</i>. 2009 Sep;166(9):980-991. doi: 10.1176/appi.ajp.2009.09030312. Epub 2009 Aug 17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/19687129 /pubmed\" target=\"_blank\" id=\"19687129 \">19687129 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Newport DJ, Calamaras MR, DeVane CL, et al, &ldquo;Atypical Antipsychotic Administration During Late Pregnancy: Placental Passage and Obstetrical Outcomes,&rdquo; <i>Am J Psychiatry</i>, 2007, 164(8):1214-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/17671284/pubmed\" target=\"_blank\" id=\"17671284\">17671284</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pacchiarotti I, Le&oacute;n-Caballero J, Murru A, et al. Mood stabilizers and antipsychotics during breastfeeding: Focus on bipolar disorder. <i>Eur Neuropsychopharmacol</i>. 2016;26(10):1562-1578.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/27568278/pubmed\" target=\"_blank\" id=\"27568278\">27568278</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16877898\"></a>Padala PR, Madison J, Monnahan M, Marcil W, Price P, Ramaswamy S, et al. Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. <i>Int Clin Psychopharmacol</i>. 2006;21(5):275-280.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/16877898/pubmed\" target=\"_blank\" id=\"16877898\">16877898</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pringsheim T, Doja A, Gorman D, et al. Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. <i>Can J Psychiatry</i>. 2012;57(3):133-143.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/22397999/pubmed\" target=\"_blank\" id=\"22397999\">22397999</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation. <i>Neuropsychopharmacology</i>. 2006;31(11):2505-13. Epub 2006 Jun 7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/16760927/pubmed\" target=\"_blank\" id=\"16760927\">16760927</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15641864\"></a>Reich DB, Winternitz S, Hennen J, Watts T, Stanculescu C. A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. <i>J Clin Psychiatry</i>. 2004;65(12):1601-1606.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/15641864/pubmed\" target=\"_blank\" id=\"15641864\">15641864</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reeves H, Batra S, May RS, Zhang R, Dahl DC, et al. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. <i>J Clin Psychiatry</i>. 2008;69(8):1228-1336.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/18681749/pubmed\" target=\"_blank\" id=\"18681749\">18681749</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B. The crossover approach to switching antipsychotics: what is the evidence? <i>Schizophr Res</i>. 2005;76(2-3):267-272. doi: 10.1016/j.schres.2005.01.009.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/15949658/pubmed\" target=\"_blank\" id=\"15949658\">15949658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173(5):543-546. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2015.173501. Accessed May 26, 2016. doi: 10.1176/appi.ajp.2015.173501.27133416</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. <i>J Clin Psychiatry</i>. 1999;60 suppl 10:5-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/10340682/pubmed\" target=\"_blank\" id=\"10340682\">10340682</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Risperdal (risperidone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Risperdal Consta (risperidone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roessner V, Plessen KJ, Rothenberger A, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. <i>Eur Child Adolesc Psychiatry</i>. 2011;20(4):173-196.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/21445724/pubmed\" target=\"_blank\" id=\"21445724\">21445724</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18278987\"></a>Rothbaum BO, Killeen TK, Davidson JR, Brady KT, Connor KM, Heekin MH. Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. <i>J Clin Psychiatry</i>. 2008;69(4):520-525.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/18278987/pubmed\" target=\"_blank\" id=\"18278987\">18278987</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12682319\"></a>Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS. A placebo-controlled trial of risperidone in Tourette syndrome. <i>Neurology</i>. 2003;60(7):1130-1135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/12682319/pubmed\" target=\"_blank\" id=\"12682319\">12682319</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17035647\"></a>Schneider LS, Tariot PN, Dagerman KS, et al, &ldquo;Effectiveness of Atypical Antipsychotic Drugs in Patients With Alzheimer's Disease,&rdquo; <i>N Engl J Med</i>, 2006, 355(15):1525-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/17035647/pubmed\" target=\"_blank\" id=\"17035647\">17035647</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soares-Weiser K, Fernandez HH. Tardive dyskinesia. <i>Semin Neurol</i>. 2007;27(2):159-169.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/17390261/pubmed\" target=\"_blank\" id=\"17390261\">17390261</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18519523\"></a>Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. <i>Am J Psychiatry</i>. 2008;165(7):844-854.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/18519523/pubmed\" target=\"_blank\" id=\"18519523\">18519523</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Suppes T, Dennehy EB, Hirschfeld RMA, et al, &ldquo;The Texas Implementation of Medication Algorithms: Update to the Algorithms for the Treatment of Bipolar I Disorder,&rdquo; <i>J Clin Psychiatry</i>, 2005, 66(7):870-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/16013903/pubmed\" target=\"_blank\" id=\"16013903\">16013903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uguz F. Second-generation antipsychotics during the lactation period: a comparative systematic review on infant safety. <i>J Clin Psychopharmacol</i>. 2016;36(3):244-252.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-drug-information/abstract-text/27028982/pubmed\" target=\"_blank\" id=\"27028982\">27028982</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9868 Version 280.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50629650\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709402\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F218658\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F218659\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F218704\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F218663\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F218683\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F218664\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F218665\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F218666\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F218631\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F218617\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F218635\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49133431\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F218634\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744895\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F218713\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F218624\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F218638\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F218621\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F218697\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F218625\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F218655\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F218627\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2888768\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F218642\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F218643\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F218629\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F218620\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F218637\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F218641\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F218644\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9868|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=risperidone-patient-drug-information\" class=\"drug drug_patient\">Risperidone: Patient drug information</a></li><li><a href=\"topic.htm?path=risperidone-pediatric-drug-information\" class=\"drug drug_pediatric\">Risperidone: Pediatric drug information</a></li></ul></div></div>","javascript":null}